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INTRODUCTION
  Coronary vasospasm secondary to chemotherapy 
induced toxicity presents with angina, elevated cardiac 
enzymes and electrocardiogram (ECG) changes.
  Cardiotoxicity is a rare but known oncologic 
emergency presenting after bolus or infusion 
administration of 5-fluorouracil (5-FU). 
  In such cases, prompt discontinuation of the drug  
and Cardiology consultation is required.
  This case presents a patient who underwent 5-FU 
induction therapy resulting in coronary vasospasm.
CASE PRESENTATION
  A 71-year-old male with a history of atrial fibrillation, 
hypertension, hyperlipidemia, COPD (On Home O2) 
and colon cancer presented to the emergency 
department with chest pain, diaphoresis and nausea. 
The day prior to presentation the patient began a 48-
hour chemotherapy induction of 5-FU.
  Presenting ECG demonstrated atrial fibrillation with 
rapid ventricular response, right bundle branch block 
and infero-lateral ST elevations (Figure 1). Troponin I 
was elevated to a peak of 0.24. The 5-FU infusion 
was stopped and the patient underwent coronary 
angiography where no coronary atherosclerotic 
disease was evident (Figure 2 and 3).
  ECG post catheterization showed resolution of  infero-
lateral ischemic changes (Figure 4)
  The patient was continued on aspirin, clopidogrel  
and atorvastatin and a long acting nitrate was added. 
The patient had no further episodes of chest pain.
  He had an extended hospital stay complicated by 
acute on chronic respiratory failure. He eventually 
recovered and was discharged for outpatient follow  
up with hematology-oncology for an alternative 
therapy for his colon cancer.
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DISCUSSION
  5-FU alone or in combination with other chemo-
therapeutic agents has become the mainstay of 
 colorectal cancer treatments.
  In rare cases (1.6%-8.5%), life-threatening coronary 
vasospasm has resulted secondary to endothelial 
dysfunction caused by 5-FU metabolites.1
  This cardiotoxicity tends to occur more commonly in 
the first cycle of administration and 72% of affected 
patients were aged greater than 55 years.1,2
  Symptoms and ECG findings at presentation are  
highly suggestive of coronary occlusion and diagnosis 
is supported by cardiac catheterization showing  
patent coronaries. 
  This toxicity responds favorably to prompt discon-
tinuation of 5-FU and the administration of antianginal 
 therapies such as calcium channel blockers.1
  If diagnosed in a timely fashion, the toxicity is 
commonly reversible and the prognosis, from a 
cardiac perspective, is favorable.
  Careful consideration is given to whether 5-FU can  
be reinstituted or whether acceptable alternative 
treatments can be safely used.
  When further doses of 5-FU are required, clinicians 
should proceed cautiously, consider using prophylactic 
antianginal therapy and monitor patients closely with a 
low threshold to discontinue therapy.1
Figure 2: AP cranial coronary angiogram image demonstrating a 
normal, dominant right coronary artery. 
Figure 3: RAO caudal coronary angiogram image demonstrating 
normal left circumflex and left anterior descending coronary 
arteries.
Figure 4: ECG tracing post cardiac catheterization demonstrating 
persistent atrial fibrillation, right bundle branch block and resolved 
infero-lateral ischemia.
Figure 1: Presenting ECG tracing demonstrating atrial fibrillation 
with rapid ventricular response, right bundle branch block and 
infero-lateral STEMI.
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